Neutralization of early pregnancy factor by passive immunization alters normal embryonic development and cytokine balance

Inmunología ◽  
2012 ◽  
Vol 31 (4) ◽  
pp. 106-114 ◽  
Author(s):  
María C. Grosso ◽  
Romina V. Bellingeri ◽  
Rüdiger Schade ◽  
Adriana B. Vivas
1992 ◽  
Vol 4 (4) ◽  
pp. 411 ◽  
Author(s):  
H Morton ◽  
AC Cavanagh ◽  
S Athanasas-Platsis ◽  
KA Quinn ◽  
BE Rolfe

Early pregnancy factor (EPF) was first described as a pregnancy-associated substance, although recent studies suggest a more general link with cell development. It is a product of actively dividing cells and its apparent functional importance to them suggests its potential as a regulator of cell proliferation. The recent discovery of EPF in platelets has provided a comparatively rich and readily available source of EPF. The purification procedures employed to isolate EPF from this source have also been applied to pregnancy serum and urine, medium conditioned by oestrous mouse ovaries (stimulated with prolactin and embryo-conditioned medium), medium conditioned by tumour cells, and serum from rats 24 h after partial hepatectomy (PH). In all instances, biological activity followed the same pattern throughout. Furthermore, the final active reversed-phase high-performance liquid chromatography fraction from all sources was bound specifically by immobilized anti-EPF monoclonal antibodies (MAbs), indicating that the active fractions produced from these diverse sources are very closely related, if not identical. Some differences have been observed in the behaviour of EPF in various conditions. EPF is produced by proliferating tumour cells and by liver cells post-PH, and passive immunization studies with anti-EPF MAbs have shown that these cells need EPF for survival. In contrast, EPF has not been detected as a product of the pre-embryo, and addition of anti-EPF MAbs to embryo cultures does not adversely affect development from the 2-cell to the blastocyst stage. Although the pre-embryo is not dependent on EPF for its development in vitro, neutralization of EPF in vivo by anti-EPF MAbs retards its development. Thus, EPF appears to play an indirect role in maintaining the pre-embryo. By virtue of its ability to suppress the delayed-type hypersensitivity reaction, it has been suggested that EPF might act as an immunological response modifier of the maternal immune system. Alternatively, the effect of EPF on lymphocytes may be to reduce the expression of all or some cytokines and this could inhibit development. Whether or not EPF acts more directly as an autocrine growth factor from around the time of implantation, when the embryo first begins synthesis of EPF, is not known and remains to be investigated.


2000 ◽  
Vol 43 (4) ◽  
pp. 223-233 ◽  
Author(s):  
S. ATHANASAS-PLATSIS ◽  
A.C. CAVANAGH ◽  
H. MORTON ◽  
C.M. CORCORAN ◽  
P.L. KAYE

1995 ◽  
Vol 41 (2) ◽  
pp. 159-163 ◽  
Author(s):  
Iwao HONTA ◽  
Kazuei ITO ◽  
Jutaro TAKAHASHI ◽  
Yasuhisa YASUDA

1984 ◽  
Vol 101 (1) ◽  
pp. 95-NP ◽  
Author(s):  
M.-Y. Wang ◽  
V. Rider ◽  
R. B. Heap ◽  
A. Feinstein

ABSTRACT Anti-progesterone monoclonal antibody injected intraperitoneally as a single dose 32 h post coitum completely blocked pregnancy in BALB/c and CBA nulliparous mice. The dose required was greater in CBA than in BALB/c females, but in both strains no implantation sites were detectable at autopsy on day 10 after mating. The action of the antibody in BALB/c females was associated with a failure to initiate an implantation response as indicated by the Pontamine Blue reaction. The most pronounced effect, however, was an arrest of embryonic development at a stage prior to cavitation. Plasma progesterone concentration in blood taken by cardiac puncture was greatly increased after treatment, by virtue of high-affinity binding by antibody in circulation. The results show that passive immunization against progesterone shortly after mating interferes with early hormone-dependent steps which are essential for normal embryonic development. J. Endocr. (1984) 101, 95–100


Reproduction ◽  
1989 ◽  
Vol 87 (2) ◽  
pp. 495-502 ◽  
Author(s):  
S. Athanasas-Platsis ◽  
K. A. Quinn ◽  
T-Y. Wong ◽  
B. E. Rolfe ◽  
A. C. Cavanagh ◽  
...  

Reproduction ◽  
1991 ◽  
Vol 92 (2) ◽  
pp. 443-451 ◽  
Author(s):  
S. Athanasas-Platsis ◽  
H. Morton ◽  
G. F. Dunglison ◽  
P. L. Kaye

Animals ◽  
2021 ◽  
Vol 11 (6) ◽  
pp. 1666
Author(s):  
Ottó Szenci

One of the most recent techniques for the on-farm diagnosis of early pregnancy (EP) in cattle is B-mode ultrasonography. Under field conditions, acceptable results may be achieved with ultrasonography from Days 25 to 30 post-AI. The reliability of the test greatly depends on the frequency of the transducer used, the skill of the examiner, the criterion used for a positive pregnancy diagnosis (PD), and the position of the uterus in the pelvic inlet. Non-pregnant animals can be selected accurately by evaluating blood flow in the corpus luteum around Day 20 after AI, meaning we can substantially improve the reproductive efficiency of our herd. Pregnancy protein assays (PSPB, PAG-1, and PSP60 RIA, commercial ELISA or rapid visual ELISA tests) may provide an alternative method to ultrasonography for determining early pregnancy or late embryonic/early fetal mortality (LEM/EFM) in dairy cows. Although the early pregnancy factor is the earliest specific indicator of fertilization, at present, its detection is entirely dependent on the use of the rosette inhibition test; therefore, its use in the field needs further developments. Recently found biomarkers like interferon-tau stimulated genes or microRNAs may help us diagnose early pregnancy in dairy cows; however, these tests need further developments before their general use in the farms becomes possible.


Sign in / Sign up

Export Citation Format

Share Document